# Infinity Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infinity-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.infi.com
- Total disclosed funding: $70M
- Latest round: Series B (Jun 24, 2002)
- Investors on record: 10

## About

Based in Massachusetts, US, and founded in 2001 Infinity Pharmaceuticals, Inc. operates as a developer of medicines for the treatment of cancer. In August 2009, Infinity Pharmaceuticals, Inc. become a publicly listed company on the NASDAQ and has approximately 398 employees.

The company's developed products and those under development include therapies targeting hematologic malignancies, or blood cancers; refractory indolent non-Hodgkin lymphoma; refractory chronic lymphocytic leukemia; and solid tumors, including melanoma and non-small cell lung cancer.

The company generates revenue by offering the developed therapies to pharmaceutical companies.

The company’s future strategy includes further expansion of its clinical development of eganelisib, an experimental drug being investigated as a possible treatment for cancer.

## Funding rounds

- Series B, Jun 24, 2002, $70M — Prospect Venture Partners, Wellcome Trust, HBM Partners, Tallwood Venture Capital, Novartis Venture Fund, Venrock, Alexandria Venture Investments, Vulcan, Lotus Biosciences Ventures, Advent Life Sciences

## Investors

- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series B
- Wellcome Trust — Series B
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series B
- Tallwood Venture Capital (https://capitalatlas.ai/funds/tallwood-venture-capital) — Series B
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B
- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series B
- Vulcan (https://capitalatlas.ai/funds/vulcan) — Series B
- Lotus Biosciences Ventures (https://capitalatlas.ai/funds/lotus-biosciences-ventures) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B